Search Results - "Suchard, Suzanne"

Refine Results
  1. 1
  2. 2

    Inhibition of Donor-Reactive CD8+ T Cell Responses by Selective CD28 Blockade Is Independent of Reduced ICOS Expression by Liu, Danya, Suchard, Suzanne J, Nadler, Steve G, Ford, Mandy L

    Published in PloS one (22-06-2015)
    “…Programmed T cell differentiation is critically influenced by the complement of costimulatory and coinhibitory signals transmitted during initial antigen…”
    Get full text
    Journal Article
  3. 3

    2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses by Liu, Danya, Krummey, Scott M, Badell, I Raul, Wagener, Maylene, Schneeweis, Lumelle A, Stetsko, Dawn K, Suchard, Suzanne J, Nadler, Steven G, Ford, Mandy L

    Published in The Journal of experimental medicine (10-02-2014)
    “…Mounting evidence in models of both autoimmunity and chronic viral infection suggests that the outcome of T cell activation is critically impacted by the…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation by LATEK, Robert, FLEENER, Catherine, LAMIAN, Vahideh, KULBOKAS, Edward, DAVIS, Patricia M, SUCHARD, Suzanne J, CURRAN, Mark, VINCENTI, Flavio, TOWNSEND, Robert

    Published in Transplantation (27-03-2009)
    “…The selective inhibitor of T-cell costimulation, belatacept, blocks CD28-mediated T-cell activation by binding CD80 and CD86 on antigen-presenting cells…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity by DAVIS, Patricia M, ABRAHAM, Ralph, LINDA XU, NADLER, Steven G, SUCHARD, Suzanne J

    Published in Journal of rheumatology (01-11-2007)
    “…OBJECTIVE: To assess the ability of abatacept to mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) of…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction by Davis, Patricia M, Nadler, Steven G, Stetsko, Dawn K, Suchard, Suzanne J

    Published in Clinical immunology (Orlando, Fla.) (01-01-2008)
    “…Abstract Abatacept, the first in a new class of agents for RA, modulates CD28-mediated T-cell costimulation. Abatacept was evaluated for its ability to…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16

    Abatacept Does Not Induce Direct Gene Expression Changes in Antigen-Presenting Cells by Carman, Julie A, Davis, Patricia M, Yang, Wen-Pin, Zhu, Jun, Chang, Han, He, Aiqing, Truong, Amy, Suchard, Suzanne J, Nadler, Steven G

    Published in Journal of clinical immunology (01-07-2009)
    “…Background It has been proposed that ligation of CD80 and CD86 induces reverse signaling into antigen-presenting cells. In this study, we tested the ability of…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Syk Activation Is Required for Spreading and H2O2 Release in Adherent Human Neutrophils by Fernandez, Rosemarie, Suchard, Suzanne J

    Published in The Journal of immunology (1950) (15-05-1998)
    “…Chemoattractant-stimulated polymorphonuclear leukocytes (PMNs) that are adherent to extracellular matrix proteins exhibit a massive, sustained respiratory…”
    Get full text
    Journal Article
  19. 19

    Potent Reversible Inhibitors of the Protein Tyrosine Phosphatase CD45 by Urbanek, Rebecca A, Suchard, Suzanne J, Steelman, Gary B, Knappenberger, Katharine S, Sygowski, Linda A, Veale, Chris A, Chapdelaine, Marc J

    Published in Journal of medicinal chemistry (24-05-2001)
    “…The cytosolic portion of CD45, a major transmembrane glycoprotein found on nucleated hematopoietic cells, contains protein tyrosine phosphatase activity and is…”
    Get full text
    Journal Article
  20. 20